Thomas Mueller

Thomas Mueller serves as Vice President and Head of Immuno-oncology and Translational Sciences at Trishula Therapeutics, Inc., leading strategies for molecule, pathway, and disease areas in collaboration with clinical development. In addition, Thomas runs a consulting firm specializing in R&D solutions across the drug discovery and clinical development spectrum for therapeutic and diagnostic companies. Previously, Thomas held leadership roles at Hummingbird Bioscience, Aduro Biotech, ERYTECH Pharma, Halozyme Therapeutics, and Genentech, where responsibilities included establishing and managing Translational Medicine departments, designing clinical strategies, and advancing drug development through biomarker discovery. Thomas possesses a sophisticated understanding of personalized medicine and has a robust educational background, including a PhD from the Max Planck Institute for Biochemistry and postdoctoral training at the Swiss Institute for Experimental Cancer Research.